Skip to content

Prevalence of tics, tic-severity and quality of life in Tourette syndrome in the middle-aged and elderly: an observational study

Prevalence of tics, tic-severity and quality of life in Tourette syndrome in the middle-aged and elderly: an observational study - Tourette in the elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42132
Enrollment
50
Registered
2014-09-26
Start date
2015-05-07
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tourette syndrome

Interventions

None listed

Sponsors

HagaZiekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Fulfill DSM IV criteria for Tourette syndrome Born before January 1965

Exclusion criteria

Exclusion criteria: Diagnosis of dementia Severe psychiatric disorders (e.g. psychosis) Aphasia Not able to speak and/or read Dutch language

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the total tic severity score on the Dutch version of the Yale Global Tic Severity Scale (YGTSS). The YGTSS is a well-established, semi-structured clinician derived rating scale with satisfactory convergent and discriminant validity and interrater agreement. Information on tic severity is acquired for motor tics and vocal tics separately in five dimensions: number, frequency, intensity, complexity, and interference. These dimensions are summated and the subscale scores are obtained. A rating of impairment is added to provide a total tic severity score that ranges from 0 (no tics) to 55 (severe tics).

Secondary

MeasureTime frame
Secondary outcome measurements include general assessment of quality of life, severity of premonitory urges and severity of comorbidity. The presence of neuropsychiatric comorbidity will be assessed by a validated mini neuropsychiatric interview (M.I.N.I.). If ADHD is present, severity is measured with the Conners' Adult ADHD Rating Scales (CAARS). In case of comorbid OCD, the Yale Brown Obsessive Compulsive Scale is administered. Autism is measured with the Autism Spectrum Quotient. Depression will be measured using the Beck Depression Inventory Scale. Co-occurrence of migraine will be assessed using a semi-structured headache questionnaire. Quality of life is measured using the Gilles de la Tourette Syndrome*Quality of Life Scale. The GTS-QOL is a 27-item, patient-reported scale which measures GTS-specific health related quality of life on 4 subscales (psychological, physical, obsessional, and cognitive subscale). The GTS-QOL demonstrated satisfactory scaling assumptions and acceptability, high internal consistency high reliability and test-retest reliability, and supported validity. It takes into account the complexity of the clinical picture of GTS. Health related quality of life (HRQOL) will be assessed using the TNO-AZL questionnaire for Adult*s HRQOL (TAAQOL). This questionnaire measures health status problems weighted by the impact of problems on well-being on 12 multi-item scales: gross motor functioning, fine motor functioning, cognitive functioning, sleep, pain, social functioning, daily activities, sexuality, vitality, positive emotions, depressive emotions and aggressiveness. Higher scores indicate a better HRQOL (range 0-100). Scores will be compared with an age-matched Dutch reference group provided by TNO. Psychometric performance (reliability and validity) of the TAAQOL is satisfactory.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)